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ABSTRACT OF THE DISSERTATION
Curcumin: A multi-dimensional Approach to Pancreatic Cancer
Targeting Cell Death and Exosomes
by
Carlos J. Díaz Osterman
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Dr. Nathan R. Wall, Chairperson

Pancreatic cancer is currently one of the most difficult diseases to treat due to
difficulty of detection and the aggressive nature of the disease. In addition, pancreatic
cancer has the highest mortality rates compared to other cancer types. These mortality
rates are attributable in part to increasing resistance to cancer therapy. Cancer therapy
resistance is caused by adaptations that favor survival within cancer cells and their
environment, termed the tumor microenvironment. Intracellular adaptations include the
overexpression of resistance-linked genes, such as the inhibitor of apoptosis (IAP) family
of proteins and overall resistance to cell death. Adaptations in the tumor
microenvironment include altered intercellular vesicular signaling through exosomes,
resulting in tumor growth and progression. However, recent studies have shown that
exosomes can also be used as a delivery mechanism for drugs with poor bioavailability,
thus providing a therapeutic advantage for these compounds. Currently, researchers are
moving toward a multi-dimensional approach to pancreatic cancer therapy that
incorporates compounds that target crucial players in chemotherapy resistance and in the
tumor microenvironment, such as exosomes. Our studies are centered on the anti-cancer
properties of curcumin, a turmeric derivative, on these intracellular and intercellular
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resistance mechanisms. The long term goal of this research is to determine the
mechanisms by which curcumin modulates intracellular pathways related to pancreatic
cancer survival and therapy resistance and exosome composition and release to improve
the understanding of pancreatic cancer pathology and support the development of novel
therapeutic approaches for pancreatic cancer patients. The specific objective of this
research was to determine curcumin’s role in modulating intracellular proteins imperative
for pancreatic cancer chemotherapy resistance such as the IAP proteins. Moreover, this
research addressed the effects of curcumin on exosome release and function, specifically
in the context of delivery to recipient pancreatic cancer cells. We have established that
curcumin reduces expression of the IAPs in pancreatic cancer cells, inhibiting their
survival and growth. Furthermore, curcumin not only attenuates pro-survival signaling
through exosomes, but also itself carried within the nanovesicles and delivered to
recipient pancreatic cancer cells, resulting in pancreatic cancer cell death.
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CHAPTER ONE
CURCUMIN AND PANCREATIC CANCER: A RESEARCH AND CLINICAL
UPDATE

Carlos J. Díaz Osterman and Nathan R. Wall

Center for Health Disparities and Molecular Medicine
Department of Basic Sciences
Division of Biochemistry
Loma Linda University
Loma Linda, California, 92350

Adapted from Díaz Osterman, C.J., et al. Journal of Nature and Science (2015) 6, e124
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Abstract
Pancreatic cancer is currently one of the most deadly types of cancer. Poor patient
prognosis is linked to the lack of effective early detection techniques and emerging
resistance to current therapeutic strategies. Thus, current research efforts are focusing on
overcoming drug resistance. One branch of this field of study is the use of natural
compounds to combat pancreatic cancer and drug resistance. Curcumin, a turmeric
derivative, is one such compound that has been shown to have potent anti-cancer
properties in the context of pancreatic cancer. However, curcumin’s poor bioavailability
limits its clinical utility. Multiple approaches have been taken to overcome this problem,
including curcumin modifications, curcumin combination therapy with other natural and
synthetic therapeutic agents and the use of nano-formulations. This review is intended to
provide a compendium of the cutting-edge investigations related to preclinical and
clinical uses of curcumin, including its analogues and nano-formulations, in the context
of pancreatic cancer.
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Introduction
Pancreatic cancer is one of the most devastating types of cancer. The American
Cancer Society has estimated that 48,960 individuals will be diagnosed with pancreatic
cancer in the United States this year. Furthermore, approximately 40,560 of these patients
(83%) will perish from this disease this year and only 7% of patients will survive at least
five years [1]. Inadequate detection techniques, the aggressive nature of the disease, and
the emerging resistance to the current treatment approaches have contributed to these
unacceptably high mortality rates [2]. Tumor removal in combination with post-surgical
chemotherapy treatment is considered the most effective treatment approach to date.
Unfortunately, the early detection of pancreatic cancer, which is an eligibility
requirement for surgery, is challenging due to the lack of accurate and reliable detection
methods. However, patients that are ineligible for surgery still have the option to receive
a battery of chemotherapeutic agents in combination with radiation therapy. Most
combinational therapies consist of using anti-metabolites, DNA damage inducers,
tyrosine kinase inhibitors and topoisomerase inhibitors, with the gold standard
chemotherapeutic agent for pancreatic cancer being Gemcitabine, an anti-metabolite and
inducer of DNA damage. However, despite clinical responses in some cases, overall
patient survival and quality of life are not improved by these therapies [3-8]. The chemoor radiation-therapy resistance developed by most patients with pancreatic cancer has
hindered the efficacy of combinational chemotherapeutic and radiation-based treatment
strategies [9]. Thus, a better understanding of the mechanisms of therapeutic resistance
and the development of novel therapeutic approaches are of paramount importance to the
eradication of this disease.
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A low incidence of cancer has been documented in countries that incorporate high
consumption of turmeric root into their diets [10, 11]. This association has been
extensively investigated, particularly in the context of the biological roles of turmeric
root derivatives. Curcumin is a derivative of the turmeric root that has been extensively
investigated because of its low toxicity in normal tissues and capacity to hinder multiple
signaling pathways that are crucial for the initiation and progression of various cancers,
including pancreatic cancer [12]. Additionally, curcumin has been shown to
synergistically enhance the anti-cancer effects of standard chemotherapeutic agents,
including Gemcitabine, in pancreatic cancer [13]. Due to curcumin’s poor bioavailability
in clinical trials involving pancreatic cancer patients [14-17], novel approaches such as
curcumin analogues and nano-particle formulations of curcumin have been developed
[14, 18, 19] and are currently under investigation in various cancers [20-25], including
pancreatic cancer [18, 26-28]. Currently, the literature concerning the pre-clinical and
clinical anti-cancer properties of curcumin in various cancer types has been eloquently
reviewed [12, 29, 30]; however, a comprehensive review addressing the current state of
curcumin research in the context of pancreatic cancer is lacking. Therefore, the purpose
of this review is to provide a compilation of cutting-edge studies involving the preclinical and clinical utility of curcumin and its analogues and nano-formulations in
pancreatic cancer.

Curcumin: Molecular Mechanisms in Pancreatic Cancer
Vogel and Pelletier were the pioneers in obtaining the yellow crystalline form of
curcumin from the turmeric root in 1818 [31]. Nevertheless, it was not until 1870 that

4

Daube elucidated the structure of curcumin as 1,6-heptadiene-3,5-dione-1,7-bis(4hydroxy-3-methoxyphenyl)-(1E,6E) or diferuloylmethane (Fig. 1) [31]. The discovery of
the structure of curcumin paved the way for the investigation of its remarkable anticancer
properties. In particular, curcumin’s effects in pancreatic cancer have been widely
studied. It has been shown to influence a range of cellular functions including
proliferation, survival, angiogenesis, and invasion and metastasis. For instance, curcumin
causes G2/M cell cycle arrest in pancreatic cancer cells following DNA damage and
ATM-Chk1-dependent inhibition of CDK-1 and Cyclin B1 activity [32]. Interestingly,
this study also demonstrated that curcumin showed lower cytotoxic effects and no DNA
damage or cell cycle arrest in normal human pancreatic ductal epithelial cells [32].
Curcumin also has potent effects on cell survival, most notably through regulation of the
inhibitor of apoptosis (IAP) family, which includes Survivin, cellular IAPs 1 and 2
(cIAP1 and cIAP2) and X-chromosome linked IAP (XIAP). One of the key roles of the
IAP proteins in normal cells is to modulate the balance between cell survival and cell
death. The unbalanced regulation of IAP proteins can drive cells to a more pro-survival
phenotype. Indeed, pancreatic cancer cells overexpress IAP proteins and the
overexpression of these proteins is associated with poor patient outcomes in pancreatic
cancer [33-36]. In addition, studies have demonstrated that resistance to radiation and
chemotherapy are also related to the overexpression of the IAP proteins [37-44]. Studies
from our laboratory have demonstrated that although other standard chemotherapeutic
agents are ineffective at reducing these IAP family members [45], curcumin abolishes
Survivin, cIAPs 1 and 2, and XIAP protein and mRNA expression in pancreatic cancer
cells [46]. This is consistent with previous reports that Survivin expression is reduced
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following curcumin treatment in pancreatic cancer cells as a result of inhibition of
upstream STAT3 signaling [47] or reduction in NF-κB activity [48]. The importance of
STAT3 and NF-κB signaling in pancreatic cancer has been well established [49, 50].
Interestingly, Jutooru et al. also demonstrated that curcumin reduces Sp1 and NF-κB
activity, resulting in downregulation of downstream genes including Survivin, MMP-9,
VEGF and Cyclin D1. Furthermore, these studies demonstrated that reduction in NF-κB
activity was dependent on Sp1 reduction following curcumin treatment, suggesting that
curcumin’s effects on Sp1 represent an upstream event in pancreatic cancer cells [51].
Studies by Sun et al. complement these findings by demonstrating that curcumin
modulates microRNA (miRNA) expression profiles in pancreatic cancer cells [52].
MiRNAs are small non-coding RNAs [53-55] that have recently gained increased
attention in the literature due to their involvement in important biological processes via
post-transcriptional modulation of gene expression [54-57]. Altered post-transcriptional
gene regulation conferred by miRNAs has been linked to pancreatic cancer [58]. One
miRNA that is altered after curcumin treatment is miRNA-22, whose increased
expression after treatment results in downregulation of target transcripts for Sp1 and
estrogen receptor 1 (ESR1) [52]. Another study concluded that curcumin inhibits
pancreatic cancer cell growth and invasion via upregulation of miRNA-7 and subsequent
downregulation of SET8, which is known to promote tumorigenesis [59], and activation
of p53 [60]. This is consistent with studies demonstrating the essential role of miRNA-7
in the regulation of tumor growth and metastasis in chemoresistant cancer cells [61].
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In addition to miRNA-mediated regulation, curcumin has also been shown to
modulate gene expression at the post-transcriptional level by altering the expression RNA
binding protein CELF2 (CUGBP, Elav-like family member 2), a known regulator of
RNA splicing, editing, and translation [62-65]. Curcumin induces CELF2 expression in
pancreatic cancer cells, resulting in decreased translation of VEGF and COX-2 and
overall reduction in tumor growth and angiogenesis in a pancreatic cancer xenograft
model [66].
Finally, curcumin has been shown to combat chemotherapeutic resistance through
reduction IAP expression, as described above, as well as via inhibition of the ATPdependent multidrug resistance protein-5 (MRP5), an efflux pump notorious for
promoting the export of chemotherapeutic drugs [67]. Interestingly, curcumin has been
shown to suppress the activity of MRP5 and enhance the effects of 5-fluorouracil (5-FU)
in pancreatic cancer [68]. In summary, curcumin’s effects in pancreatic cancer are truly
multi-dimensional, regulating miRNA expression, transcription factor activity and gene
expression resulting in increased cell death and reduced pro-angiogenic, metastatic, and
chemoresistant signaling. It is important to note that although several STAT3 inhibitors
(NCT00955812, NCT02058017, NCT01423903, NCT01867073, NCT01563302,
NCT01839604) and IAP antisense compounds (NCT000882869, NCT00557596,
NCT00558545, NCT01018069, NCT00372736, NCT01186328, NCT00620321) have
been studied in various phase I/II clinical trials, the majority of curcumin’s targets have
yet to be addressed in clinical trials. Furthermore, no compound has been demonstrated to
possess the vast arsenal of anti-cancer mechanisms displayed by curcumin.
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Curcumin: Analogues and Nano-formulations in Pancreatic Cancer
Curcumin Analogues in Pancreatic Cancer
The metabolism of curcumin involves hepatic enzymes such as glucuronidases
and sulfotransferases, which are responsible for conjugating glucuronic acid or sulfate,
respectively, to the hydroxyl groups on the ketone or enol forms of curcumin [69, 70].
These reactions enhance the hydrophilic potential of curcumin, facilitating its elimination
[69, 70]. Unfortunately, these systemic clearance mechanisms are responsible for
hindering curcumin’s delivery to tumors [69]. Thus, the development of analogues of
curcumin has focused on modifying the hydroxyl and other functional groups on the
ketone or enol forms of curcumin to ensure greater stability and longevity of the
compound in circulation (Fig. 1).
Early studies by Aggarwal et al. investigated the anti-cancer activity of a [Dlys6]LHRH-curcumin conjugate. This compound was developed with the rationale that
luteinizing hormone releasing hormone (LHRH) and its corresponding receptor, LHRHR,
are important regulators of cellular proliferation in human tumors in an autocrine and
paracrine fashion [71]. Pancreatic cancer cells express higher levels of LHRH receptors
than normal cells and the importance of these receptors is highlighted by the finding that
the proliferation of cancerous cells may be interrupted in vitro using antagonists of
LHRH receptors [71-74]. The [Dlys6]-LHRH-curcumin conjugate was found to suppress
pancreatic cancer growth in xenograft mice with higher efficacy compared to unmodified
curcumin [73].
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PEGylated-curcumin

Curcumin

[Dlys6]-LHRH-curcumin
FLLL11

FLLL12

GO-Y030

FLLL31

CDF

FLLL32

EF31

UBS 109

Figure 1. Curcumin and its analogues. Chemical structures of curcumin (blue box) and
its analogues are shown. PEGylated curcumin = polyethylene glycol-conjugated
curcumin, [Dlys6]-LHRH-curcumin = luteinizing hormone releasing hormone-conjugated
curcumin, CDF = difluorinated curcumin.
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Curcumin has also been conjugated to a water-soluble polyethylene glycol
compound (PEGylated curcumin), which was found to enhance curcumin’s ability to
suppress pancreatic cancer growth via inactivation of Jab1 [75], a protein that has been
shown to promote pancreatic cancer cell proliferation and survival [76, 77]. In addition,
PEGylated curcumin was able to sensitize pancreatic cancer cells to Gemcitabine,
inducing apoptosis [75].
Curcumin has been modified through the addition of methyl or cyclohexyl
functional groups, yielding analogues FLLL31 and FLLL32. These compounds have
been demonstrated to have anti-proliferative and anti-angiogenic effects in addition to
their ability to attenuate STAT3 activity in vitro. Interestingly, FLLL32 also exerts antitumor effects in vivo [78]. Analogues FLLL11 and FLLL12, characterized by ketone
elimination and ether modifications, have also been investigated in the context of STAT3
and pancreatic cancer; these compounds are more effective than curcumin at inducing
apoptosis via inhibition of STAT3 and AKT phosphorylation [18]. A similar analogue,
GO-Y030, also inhibits phosphorylation and activation of STAT3 in pancreatic cancer
cells, inducing apoptosis [79].
The addition of pyridine and piperidine moieties has yielded novel curcumin
analogues UBS109 and EF31. These compounds have also been tested in pancreatic
cancer and have been shown to influence DNA methylation patterns through modulation
of DNA methyltransferase (DNMT)-1 expression [80]. Furthermore, these analogues
have increased anti-angiogenic effects in in vitro and in vivo models of pancreatic cancer
through inhibition of NF-κB activity and reduction of HIF-1α and VEGF expression [26].
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Difluorinated curcumin (CDF) has been shown to sensitize pancreatic cancer cell
lines to Gemcitabine through inhibition of NF-κB and COX-2 [81]. CDF is also a
suppressor of tumor growth via the reduction of histone methyltransferase EZH2, Notch1, CD44, EpCAM and Nanog in an orthotropic xenograft pancreatic cancer model [82].
Furthermore, CDF has been demonstrated to influence miRNA expression profiles in
pancreatic cancer. In particular, CDF upregulates miRNA-146a and downregulates
miRNAs -21 and -221 in pancreatic cancer. MiRNA-146a has gained attention in
pancreatic cancer because its downregulation is associated with high levels of EGFR and
induction of NF-κB [83]. Recently, CDF has been shown to increase the expression of
miRNA-146a resulting in a reduction in EGFR protein levels in a pancreatic cancer
xenograft mouse model [84]. It has been previously demonstrated that miRNA-21
upregulation in pancreatic cancer cells is linked to inactivation of the tumor suppressor
gene PTEN following the induction of the PI3K/Akt/mTOR pathway [85, 86].
Interestingly, CDF has been reported to decrease miRNA-21 expression, resulting in
restoration of PTEN activity in vitro and in vivo [81, 82]. Moreover, this study concluded
that CDF is able to stall tumor progression in a pancreatic cancer xenograft mouse model
via modulation of COX-2, PTEN, miRNA-21, miRNA-200 and NF-κB [82, 87].
MiRNA-221 is present in high levels in pancreatic cancer cell lines and tumor tissues in
contrast to normal pancreatic duct epithelial cells and normal pancreas tissues [88, 89].
CDF decreases the expression of miR-221 and activates PTEN, p27kip1, p57kip2 and
PUMA leading to suppression of pancreatic cancer cell proliferation and migration [89].
Taken together, these studies demonstrate that curcumin analogues have
significant anti-tumor effects in pancreatic cancer, suggesting that they are promising
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candidates for evaluation in clinical trials. To date, however, there have been no clinical
trials involving these compounds, though most curcumin analogues have shown clear
benefits in preclinical modes of pancreatic cancer. Thus, these analogues represent a
promising “next step” in the incorporation of curcumin into the clinical treatment
regiment for pancreatic cancer patients.
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Table 1. Enhancement of curcumin bioavailability and stability: curcumin analogues.
Name

Preclinical Data

Ref.

[Dlys6]-LHRH-curcumin

Decreases tumor growth in vivo

[73]

GO-Y030

Inhibits STAT3 activation and induces apoptosis in vitro

[79]

FLLL11 and FLLL12

Inhibit STAT3 and AKT phosphorylation and activation and
induce apoptosis in vitro

[18]

FLLL31 and FLLL32

Anti-proliferative and anti-angiogenic effects

[78]

Attenuate STAT3 activity in vitro (both compounds)
Anti-tumor effects in vivo (only FLLL32)
PEGylated-curcumin

Suppresses cancer growth via inactivation of Jab1 and enhances
Gemcitabine in vitro

[75]

EF31 and UBS109

Anti-angiogenic

[26, 80]

Enhance oxiplatin and 5FU efficacy

CDF

Modulate DNMT-1 expression
Decreases the expression of miR-21 leading to PTEN activation
in vitro and in vivo
Stop tumor progression in vivo via modulation of COX-2,
PTEN, miR-21, miR-200 and NF-κB
Enhances Gemcitabine efficacy in vitro
Increases miR-146a leading to a decrease of EGFR expression
in vivo
Decreases miR-221 and increases expression of PTEN, p22,
p57 and PUMA leading to a decrease in cell proliferation ad
migration in vitro
Decreases tumor growth via down-regulation of EZH2, Notch1, CD44, EpCAM and Nanog in vivo
Increases the expression of miR-26a, miR-143 and miR-101
and decreases let-7 levels in vitro
Down-regulates Ras and reduces tumor growth
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[81, 82, 84, 87,
89, 90]

Curcumin Nano-formulations in Pancreatic Cancer
Early studies by Li et al. demonstrated that liposomal preparations of curcumin
involving lipids 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] sodium salt (DMPG) reduced cell
viability in six pancreatic cancer cell lines as well as tumor volume in a pancreatic cancer
xenograft model. Like curcumin, liposomal curcumin abolishes NF-κB binding in
pancreatic cell lines, resulting in reduced expression of downstream target genes such as
COX-2, IL-8 and VEGF in vitro and in vivo [91]. Mach et al. built on this work by
establishing a putative dosing regimen for preclinical and clinical trials based on the
minimum effective dose of liposomal curcumin in a MIA PaCa-2-derived xenograft
model [28]. Another study involving lipid-based curcumin found that combination with
nano-encapsulated aspirin and free sulforaphane was more efficient than curcumin alone
at inducing apoptosis in human pancreatic cancer cell lines [92]. Curcumin nanoformulations can be also prepared using sugar molecules instead of lipids arranged in a
cyclic fashion [93]. A recent example is rubusoside-solubilized curcumin, thought to
form nanomicelles in water, that has improved water solubility and equivalent
cytotoxicity in various cancer cell lines, including the pancreatic cancer cell line PANC1, compared to free curcumin [94]. A separate study showed that the curcumin analogue
CDF may be packaged within sugar structures termed cyclodextrins and retain its anticancer properties upon delivery to pancreatic cancer cells [93]. Furthermore, this study
reported that the serum levels of nano-CDF were 10 times higher than CDF alone [93].
In 2007, Bisht et al. developed a micelle-based polymeric nanoparticle
encapsulation of curcumin called nanocurcumin, or NanoCurc. In early studies, the in
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vitro cytotoxicity of nanocurcumin was tested against eight pancreatic cancer cell lines,
demonstrating comparable efficacy to free curcumin in most cell lines. Like free
curcumin, nanocurcumin blocks NF-κB activity and reduces the expression of NF-κBregulated genes including IL-6, IL-8, and TNF-α, which are known pro-inflammatory
cytokines [95]. These studies were later expanded to include combination therapy
involving NanoCurc and Gemcitabine in a preclinical xenograft pancreatic cancer model,
resulting in suppression of tumor growth via reduction of NF-κB activity as well as
MMP-9 and Cyclin D1 expression [96].
Recently, magnetic particles have been used to encapsulate curcumin to prolong
curcumin’s delivery to tumor tissues in a pancreatic cancer xenograft model. These
curcumin-loaded magnetic particles were found to suppress pancreatic tumor growth,
improving survival by downregulating pro-survival proteins such as BCL-XL, MCL-1
and PCNA. Importantly, increased β-catenin and reduced collagen I expression were
detected following treatment with magnetic nanoparticle-based curcumin, suggesting
possible effects on metastatic activity in this model [97].
Another recent nano-formulation was developed by Wei et al., involving the
ester-mediated conjugation of curcumin to cholesteryl-hyaluronic acid (CHA) nanogel
that targets curcumin to CD44 (a cell surface receptor for hyaluronic acid)-expressing
cells. This formulation was tested in a MIA PaCa-2-based xenograft model,
demonstrating significant reduction in tumor growth compared to free curcumin. In
addition, CHA-nanogel curcumin also reduced the mRNA expression of NF-κB and
target genes TNF-α and COX-2 compared to control [98].
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Although these nano-formulations of curcumin have shown strong promise for
integration into therapeutic approaches to pancreatic cancer, they have yet to be tested in
clinical trials. Of the nano-formulations developed to date, Theracurmin, a colloidal
nano-formulation using gum ghatti derived from ghatti trees, has shown the most
progress and translatability. First described in 2011 by Sasaki et al., Theracurmin was
found to significantly increase curcumin’s bioavailability in healthy human volunteers
[99]. In 2014, Kanai reported the results of a phase I clinical trial of Theracurmin in
patients with pancreatic cancer in combination with Gemcitabine. This study reported
that curcumin did not cause any unexpected adverse effects aside from abdominal pain in
a subset of patients with peritonitis carcinomatosa. Furthermore, quality of life scores
were significantly improved following Theracurmin incorporation as part of the
therapeutic strategy [100].
Most recently, nano-scale extracellular vesicles called exosomes have been shown
to target intercellular transporters of bioactive molecules that can modulate cancer growth
[101-106]. In addition, studies have shown that exosomal transport between cancer cells
can be used as a therapeutic advantage. Specifically, Aspe et al. have shown that
exosomes isolated from melanoma cell lines overexpressing the pro-apoptotic SurvivinT34A mutant carry the mutant Survivin into the pancreatic adenocarcinoma cell line MIA
PaCa-2, inducing apoptotic cell death [107]. Furthermore, the exosomal uptake of
Survivin-T34A mutant by pancreatic cancer cells enhanced their sensitivity to
Gemcitabine [107]. In the context of curcumin, our studies have shown that exosomes
extend the anti-cancer properties of curcumin from treated to naïve pancreatic
adenocarcinoma cells [108]. Specifically, exosomes isolated from PANC-1 cells treated
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with curcumin were found to contain curcumin. Furthermore, these curcumin-containing
exosomes reduced the viability of naïve PANC-1 cells [108]. The exosomal ability to
carry functional curcumin between cells represents an exciting new direction in curcumin
research: the extension of curcumin’s effects to other cellular components of tumors via
exosomal delivery. In summary, nano- and microvesicular formulations of curcumin may
represent a gateway to translating the known anti-cancer properties of curcumin to patient
care by overcoming key obstacles such as biodistribution and compound stability.

Table 2. Enhancement of curcumin using nano-formulations.
Nano-formulation

Preclinical or Clinical Data

Ref.

Rubusoside-based

Enhances curcumin’s water solubility and anti-cancer
abilities in vitro

[94]

Liposome-based

Decreases tumor volume with no toxicity at a dose of 20
mg/kg in vivo

[28, 91]

Exhibits anti-angiogenic properties and decreases CD31 and
IL-8 in vivo
NanoCurc

In combination with Gemcitabine, suppresses tumor growth
substantially via reduction of NF-κB, MMP-9 and Cyclin D1
expression in vivo

[96]

Magnetic-based

Promotes enhancement of curcumin delivery for up to 2-3
weeks and suppression of tumor growth via down-regulation
of BCL-XL, MCL-1, PCNA and collagen 1

[97]

CHA-Nanogel

Provides superior curcumin biodistribution and slower
elimination and suppresses tumor growth in vivo

[98]

Theracurmin

Increases curcumin’s plasma levels in patients with minimal
toxicity

[14, 109]
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Curcumin: Clinical Utility Against Pancreatic Cancer
Currently, there are several studies with the impetus to apply curcumin’s anticancer properties in pancreatic cancer patients. Phase I studies of curcumin in pancreatic
cancer patients have demonstrated low toxicity and high consumption tolerance, up to 12
grams per day, with minimal secondary effects (diarrhea and nausea) [14, 15, 17, 110,
111]. Phase II clinical trials involving curcumin treatment in patients with advanced
pancreatic cancer consisted of 25 patients, of which 21 could be evaluated. One patient
presented 18 months of disease without progression, two other patients showed partial
response and another patient exhibited brief tumor regression [112]. Consistent with
preclinical data, decreased expression of NF-κB, COX-2 and phosphorylated STAT3 was
detected in the peripheral blood mononuclear cells of patients treated with curcumin in
this study [112]. Furthermore, peak plasma delivery of curcumin in these patients was 22
to 41 ng/mL with no significant toxicity observed in patients [112]. Another phase I/II
clinical trial was designed to treat pancreatic cancer patients resistant to Gemcitabine
with curcumin [16]. This study involved 21 patients and concluded that a dose of 8 grams
of curcumin per day was appropriate since it did not induce toxicity after co-treatment
with Gemcitabine. Curcumin levels detected in the plasma of five tested patients ranged
from 29 to 412 ng/mL [16]. Furthermore, the median survival time was approximately
5.4 months and the one-year survival rate was 19% [16]. The combinational therapy
presented in this study was non-toxic and feasible; however, its efficacy remains to be
elucidated. In a similar phase II study, the feasibility and efficacy of 8 grams of curcumin
per day in combination with 1,000 mg/m2 of Gemcitabine was investigated in 17 patients
with advanced pancreatic cancer [113]. In this clinical trial the efficacy of curcumin and
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Gemcitabine treatment could be only analyzed in 11 patients because the individual and
combinational treatments were toxic to five patients and another unfortunately
succumbed to their disease [113]. At the end of the study one patient exhibited partial
response, four patients had no disease progression and six patients had disease
progression [113]. Based on these data, the study concluded that the time of disease
progression was 1-12 months and the overall survival was 1-24 months [113]. The
authors discussed that in their study 8 grams per day of curcumin is not well tolerated in
combination with Gemcitabine; however, in the light of the other studies mentioned
previously, further studies are needed to validate this conclusion [113]. In clinical trials,
curcumin has been shown to have relatively low toxicity. However, its use is still
challenged by poor biodistribution in spite of administration at high doses [14-17]. As
described above, a recent study that evaluated the bioavailability of Theracurmin, a
colloidal nano-formulation of curcumin [99], in human subjects concluded that curcumin
plasma levels were higher in patients treated with Theracurmin compared with the
patients treated with free curcumin [14]. For this reason Theracurmin has been considered
a promising treatment agent for cancer clinical trials. A phase I study involving treatment
of 14 pancreatic cancer patients with Theracurmin containing 200 and 400 mg of
curcumin in combination with Gemcitabine demonstrated that the curcumin peak plasma
levels ranged between 324 and 440 ng/mL, respectively [109]. It is note-worthy to
mention that the plasma curcumin levels using Theracurmin are higher than the curcumin
peak plasma levels, approximately 85 ng/mL, reported after 8 grams per day of free
curcumin [16]. This study showed that the efficacy of curcumin after Theracurmin
delivery in pancreatic cancer patients induced no response in general, a median survival
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time of 4.4 months for 14 patients and more than 12 months survival in three patients
[109].

Conclusion
This review summarizes a wide range of preclinical studies that have
demonstrated that curcumin is a potent anti-cancer agent alone and in combination with
standard chemotherapeutic agents. In addition, curcumin analogues and nanoformulations have shown promising effects against pancreatic cancer growth and survival
while improving curcumin bioavailability. Interestingly, curcumin’s anti-cancer effects
have recently been demonstrated to extend beyond direct intracellular effects to other
cancer cells through exosomes, suggesting that these nano-scale vesicular transporters
may play a key role in curcumin’s effects within the tumor microenvironment. In clinical
trials, curcumin alone and in combination with Gemcitabine have exhibited general
tolerability with low toxicity in pancreatic cancer patients. However, the efficacy of
curcumin in patients with pancreatic cancer requires further investigation due to
curcumin’s poor bioavailability. Several attempts using Theracurmin have been
performed to overcome this treatment obstacle, demonstrating promising results in
pancreatic cancer patients. Nevertheless, the anti-cancer effects of Theracurmin with
Gemcitabine or other chemotherapeutic agents still require attention. With significant
advances in curcumin modulation at the cellular and preclinical levels, it is the hope of
the authors that these findings will soon be translated to clinical trials, potentially
improving pancreatic cancer patient outcomes and quality of life.
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Abstract
The inhibitor of apoptosis (IAP) proteins are critical modulators of
chemotherapeutic resistance in various cancers. To address the alarming emergence of
chemotherapeutic resistance in pancreatic cancer, we investigated the efficacy of the
turmeric derivative curcumin at reducing IAP protein and mRNA expression resulting in
pancreatic cancer cell death. The pancreatic adenocarcinoma cell line PANC-1 was used
to assess curcumin’s effects in pancreatic cancer. Curcumin uptake was measured by
spectral analysis and fluorescence microscopy. AlamarBlue and Trypan blue exclusion
assays were used to determine PANC-1 cell viability following curcumin treatment.
Visualization of PANC-1 cell death was performed using Hoffman modulation contrast
microscopy. Western blot and PCR analyses were used to evaluate curcumin’s effects on
IAP protein and mRNA expression. Curcumin enters PANC-1 cells and is ubiquitously
present within the cell following treatment. Furthermore, curcumin reduces cell viability
and induces morphological changes characteristic of cell death. Additionally, curcumin
decreases IAP protein and mRNA expression in PANC-1 cells. These data demonstrate
that PANC-1 cells are sensitive to curcumin treatment. Furthermore, this work supports a
role for curcumin as part of the therapeutic approach for overcoming chemotherapeutic
resistance mediated by the IAPs in pancreatic cancer.
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Introduction
Pancreatic cancer is an aggressive and devastating disease responsible for the
highest mortality rates among cancer types with 94% of patients dying within five years
of diagnosis. Pancreatic tumor resection remains the most efficacious treatment with 20
to 25% of the patients surviving five years post-surgery. However, early diagnosis, a
prerequisite for the surgery, is made difficult by the absence of early signs or symptoms
[2, 3, 114]. As a result, most patients are ineligible for the surgery at the time of diagnosis
and are offered chemotherapy [3, 114, 115]. The gold standard chemotherapeutic for
pancreatic cancer is Gemcitabine, which has shown significant clinical benefits, with
survival rates ranging from six to fifteen months when resection is not an option and the
patients exhibit either non-metastatic or metastatic disease [8, 116-118]. Unfortunately,
emerging resistance to chemotherapy has hindered the efficacy of chemotherapeutics
including Gemcitabine [9], highlighting the need for novel therapeutic approaches that
address this rising resistance to therapy.
The inhibitor of apoptosis (IAP) proteins, including Survivin, cellular IAP 1 and 2
(cIAP1 and cIAP2), and X-chromosome linked IAP (XIAP), belong to a family of antiapoptotic proteins known to confer resistance to treatment modalities such as radiation
therapy and chemotherapy [33-36]. Additionally, the overexpression of these IAP
proteins has been positively correlated with the progression of a variety of cancer types,
including pancreatic cancer, resulting in a decline in patient survival after
chemotherapeutic treatment [37-44]. Pre-clinical and clinical trials aimed at reducing IAP
expression via antisense oligonucleotides and/or second mitochondria-derived activator
of caspases (Smac) mimetics have yielded promising results in various cancers [37, 119-
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124]; however, such studies have remained inconclusive in pancreatic cancer [125]. This
may be due to a compensatory effect of IAPs to targeted therapies. Further studies
involving agents that cause simultaneous reduction in multiple IAPs are needed to
investigate this notion.
Curcumin, a turmeric derivative, has been considered as a potential anti-cancer
therapy due to its capacity to interrupt signaling pathways that are crucial for the
initiation and progression of cancer [12]. For instance, studies have demonstrated that
curcumin inhibits the progression of various cancers by modulating the expression of
anti-apoptotic factors [126-131]. Furthermore, curcumin induces apoptosis in pancreatic
cancer [18] and regulates IAP expression in a variety of other cancer types [132, 133].
Preclinical studies involving curcumin in pancreatic cancer have shown that curcumin
enhances Gemcitabine sensitivity in vitro and in vivo [48, 134, 135]. Moreover, Phase I
and II clinical trials have yielded promising results on the use of curcumin as part of
pancreatic cancer therapeutic strategies [16, 109, 112, 113, 136, 137]. This recent
progress emphasizes the need for a better understanding of the mechanisms by which
curcumin counteracts chemotherapeutic resistance. Therefore, the objective of this study
was to determine curcumin’s impact alone on IAP expression in pancreatic cancer cells.

Materials and Methods
Cells and Culture Conditions
The pancreatic adenocarcinoma cell line PANC-1 was acquired from the
American Type Culture Collection (ATCC, Manassas, VA) and maintained in
Dulbecco’s modified Eagle medium (DMEM; ATCC, Manassas, VA) supplemented with
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Normocin at a final concentration of 100 µg/mL (InvivoGen, San Diego, CA), 100 units
of penicillin, 100 µg/mL of streptomycin, 300 µg/mL of L-glutamine and 10% USDAsourced heat-inactivated fetal bovine serum (Mediatech, Manassas, VA). In all
experiments, cells were cultured at 37°C in a humidified atmosphere containing 5% CO2
to 70-80% confluency prior to use.

Preparation of Curcumin Solutions
Curcumin (Sigma-Aldrich, St. Louis, MO) stock solutions were prepared using
DMSO and ethanol as solvents. Subsequent dilutions were made from this stock solution
in DMEM. The final concentrations of DMSO and ethanol did not exceed 0.04% and
0.6%, respectively, and cell viability was not affected at these concentrations (data not
shown).

Cell Viability Assays
Cell viability following curcumin treatment was estimated using AlamarBlue and
Trypan blue exclusion assays. For AlamarBlue assays, PANC-1 cells were cultured in 96well plates at 1.0 x 104 cells per well and treated with 10, 50 and 100 µM curcumin for
24, 48 and 72 hours. Subsequently, the AlamarBlue reagent (Life Technologies, Grand
Island, NY) was added to each sample (10% final concentration) and incubated at
37°C/5% CO2 for two hours. Viability was analyzed by detection of absorbance at 570
nm using 600 nm as a reference wavelength in a µQuant spectrophotometer (Bio-Tek,
Winooski, VT). For Trypan blue exclusion assays, cells were cultured in 6-well plates at
3.0 x 105 cells per well and treated with 10, 50 and 100 µM curcumin for 24, 48 and 72
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hours. Cells were then trypsinized and combined with the Trypan blue reagent (Life
Technologies, Grand Island, NY) to calculate viability by counting the cells on a
hemacytometer. The results presented are representative of three independent
experiments. Data from curcumin-treated samples are normalized to the untreated
control.

Hoffman Modulation Contrast Microscopy
PANC-1 cells were cultured in T25 flasks at 7.0 x 105 cells per flask and treated
with 10, 50 and 100 µM curcumin for 24 and 48 hours. Cells were then imaged using an
Olympus IX70 microscope with Hoffman modulation and an Insight Spot 2 Mega
Sample camera and software. Three independent experiments were performed and within
each experiment three images were captured in different sections of the T25 flasks to
obtain a representative image.

Spectral Studies and Fluorescence Imaging
Spectral analysis of PANC-1 cell curcumin content post-treatment was performed
as previously described [138-140]. Briefly, cells were cultured in T75 flasks at 1.5 x 106
cells per flask and treated with 50 µM curcumin for 24 hours. Cells were then trypsinized,
washed three times with 1X PBS, and resuspended in 1mL of 100% methanol and
sonicated to disrupt the cell membrane integrity. The samples were then centrifuged at
10,000 rpm for 5 minutes at 4°C and the supernatant fraction collected for absorbance
analysis at 420 nm using a µQuant spectrophotometer and KC Junior software (Bio-Tek,
Winooski, VT). Untreated cells were also lysed in methanol and subjected to spectral
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analysis to determine baseline auto-fluorescence of PANC-1 cells. Methanol-only, cellfree samples were used as blank controls. Data are representative of three independent
experiments. For fluorescence microscopy of PANC-1 cell curcumin content posttreatment, PANC-1 cells were cultured in 6-well plates containing sterile cover slips at
3.0 x 105 cells per well and treated with 50 µM curcumin for 24 hours. Subsequently,
cells were fixed with 4% paraformaldehyde and incubated at -20°C overnight. The
following day, the samples were permeabilized using 0.1% Igepal in 1X PBS for 10
minutes at room temperature. The cover slips were then washed three times with 1X PBS
and placed onto slides with the nuclear stain DAPI in mounting media for 5 minutes.
Stained slides were imaged using a BZ-9000 BIOREVO fluorescence microscope
(Keyence, Itasca, IL) with a 40X magnification objective. Results are representative of
three independent experiments; within each experiment, three images were acquired from
different portions of each slide to obtain a representative image.

Western Blot Analysis
PANC-1 cells were cultured in T25 flasks at 7.0 x 105 cells per flask and treated
with 10, 50 and 100 µM curcumin for 24 and 48 hours. After treatment, lysates were
prepared using a lysis buffer composed of 50 mM Tris-HCl pH 7.5, 1% Triton-X, 0.25%
DOC, 150 mM sodium chloride, 1mM sodium orthovanadate, 20 mM sodium fluoride,
0.2 mM EGTA, 1 mM EDTA, 1 mM PMSF, 1X protease inhibitor cocktail (Roche Life
Science, Indianapolis, IN) and sonicated. To remove cell debris, samples were
centrifuged at 13,000 rpm for 20 minutes at 4°C. Protein concentration was determined
using the Pierce BCA protein assay (Thermo Scientific, Waltham, MA) according to the
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manufacturer’s protocol. Proteins (50 µg) were heated to 95°C for 5 minutes and
fractionated using 10, 12 and 15% Bis-Tris polyacrylamide gels. Proteins were
transferred onto nitrocellulose membranes (BioRad, Hercules, CA) and blocked for 1
hour at room temperature in 5% milk (w/v in 1X PBS-0.1% Tween). Subsequently,
membranes were incubated overnight at 4°C in the following primary antibody solutions
(final dilution 1:1000): rabbit polyclonal anti-Survivin (Novus, Littleton, CO), rabbit
monoclonal anti-XIAP, rabbit monocloncal anti-CIAP1, rabbit monoclonal anti-cIAP2,
and rabbit monoclonal anti-β-actin (Cell Signaling Technology, Beverly, MA).
Membranes were washed with 1X PBST three times for 15 minutes each then probed for
1 hour at room temperature with goat anti-rabbit secondary antibodies labeled with
IRDye680 LT (LI-COR Biosciences, Lincoln, Nebraska), followed by three 15-minute
washes in 1X PBST and imaging using the ODYSSEY infrared imaging system (LICOR, Biosciences, Lincoln, Nebraska). β-actin was utilized as a loading control. Data are
representative of 3-4 independent experiments. Densitometry analyses were performed
using ImageJ software (http://imagej.nih.gov/ij/).

PCR Analysis
PANC-1 cells were cultured in T25 flasks at 7.0 x 105 cells per flask and treated
with 10, 50 and 100 µM for 24 and 36 hours. Cells were then trypsinized and RNA
isolation and purification was performed using the Tri-Reagent (Sigma-Aldrich, St.
Louis, MO) following the manufacturer’s protocol. cDNA conversion was performed
using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Grand
Island, NY). These cDNA products were used in combination with forward and reverse
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primers (IDT Technologies, San Diego, CA) designated for IAP mRNA (Table 1) and
Platinum Taq DNA Polymerase (Life Technologies, Grand Island, NY) for PCR in a
MasterCycler Gradient Thermo Cycler (Eppendorf, Hamburg, Germany). The PCR
products were detected using a 1% agarose gel containing ethidium bromide and
visualized using an Alpha Innotech imager (Protein Simple, Santa Clara, CA). Data are
representative of three independent experiments. Densitometry analyses were performed
using ImageJ software.

Statistical Analysis
All statistical analyses in this study were performed using one-way ANOVA
analysis and a probability of less than an 85% confidence limit (p < 0.05) was considered
to be significant. Data are presented as mean + SEM. Statistical analyses were performed
using the Prism (Graphpad, La Jolla, CA) software.

Results
Effect of Curcumin on PANC-1 Cell Viability
PANC-1 cells were cultured in increasing concentrations of curcumin for 24-72
hours and analyzed by AlamarBlue (Fig. 2A) and Trypan blue exclusion (Fig. 2B)
viability assays. Curcumin demonstrated a significant dose- and time-dependent
inhibitory effect on PANC-1 cell viability when compared with untreated controls.
Curcumin concentrations (10 and 50 µM) flanking the IC50 were chosen for further
experiments.
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Table 3. Primer sequences targeting IAPs
Name

Primer Sequence

Survivin Fwd

5’ – GCA TGG GTG CCC CGA CGT TG – 3’

Survivin Rev

5’ – GCT CCG GCC AGA GGC CTC AA – 3’

cIAP1 Fwd

5’ – ATT GTG TCA GCA CTT CTT AAT G – 3’

cIAP1 Rev

5’ – TTA AGA GAG AAA TGT ACG AAC AGT – 3’

cIAP2 Fwd

5’ – TGG AGA AGA CCA TTC AGA AGA T – 3’

cIAP2 Rev

5’ – TCA TGA AAG AAA TGT ACG AAC TGT – 3’

XIAP Fwd

5’ – ATG ACT TTT AAC AGT TTT GAA GGA – 3’

XIAP Rev

5’ – TTA AGA CAT AAA AAT TTT TTG CTT – 3’

GAPDH Fwd

5’ – ACG GAT TTG GTC GTA TTG GGC G – 3’

GAPDH Rev

5’ – CTC CTG GAA GAT GGT GAT GG – 3’

Primer sequences targeting IAPs. IAP = inhibitor of apoptosis, cIAP1 = cellular inhibitor
of apoptosis 1, cIAP2 = cellular inhibitor of apoptosis 2, XIAP = X-chromosome linked
inhibitor of apoptosis, GAPDH = glyceraldehyde 3-phosphate dehydrogenase, Fwd =
forward
primer,
Rev
=
reverse
primer.
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Figure 2. Curcumin induces PANC-1 cell death, analyzed by AlamarBlue and Trypan
blue exclusion assays. PANC-1 cells were cultured in medium supplemented with
curcumin at increasing doses for 24, 48, and 72 hours followed by (A) AlamarBlue and
(B) Trypan blue exclusion viability assays. Data are presented as mean (+SEM). * p <
0.05, ◊ p < 0.01, § p < 0.001, ‡ p < 0.0001, curcumin treatment versus untreated control.
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Effect of Curcumin on PANC-1 Cell Morphology
Apoptosis is a type of cell death with distinctive morphological features. To
qualitatively evaluate the effects of curcumin treatment on PANC-1 cellular morphology,
images were acquired using Hoffmann modulation contrast microscopy (Fig. 3). These
images illustrate an increase in cell death in a dose- and time-dependent manner. The
presence of membrane blebs and cell shrinkage, which are main morphological hallmarks
of apoptotic cells, were observed following 50 and 100 µM curcumin treatment for 24
and 48 hours.

Curcumin Detection within Treated PANC-1 Cells
It has been reported previously that curcumin has excitation and emission spectra
of 420 and 470 nm, respectively [138-140]. These spectral properties of curcumin were
used to detect its presence within PANC-1 cells using spectrophotometric studies and
fluorescence microscopy. PANC-1 cells were cultured in the presence of 50 µM
curcumin for 24 hours and subsequently washed, trypsinized, and lysed in 100%
methanol. The emission peak of curcumin-treated cell lysates at 420 nm (red) was
detected compared to cells not treated with curcumin (green) or blank/methanol-only
samples (blue) (Fig. 4A). This peak is identical to the emission spectrum of 50 µM
curcumin in methanol (data not shown). The intrinsic fluorescence of curcumin was also
exploited using fluorescence microscopy to visualize curcumin content in treated versus
untreated PANC-1 cells (Fig. 4B). The DNA dye DAPI was used to visualize nuclei
(blue). Curcumin demonstrates a pan-cellular staining pattern (green), within
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Figure 3. Morphology of curcumin-treated PANC-1 cells, visualized by Hoffman modulation contrast microscopy. PANC-1 cells
were cultured in medium supplemented with curcumin at increasing doses for 24 and 48 hours followed by imaging via Hoffman
modulation contrast microscopy. White arrows indicate membrane blebs and cell shrinkage, morphological hallmarks of
apoptosis. Results depicted in the figure are representative of findings from 3 independent experiments.
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Figure 4. Curcumin in pancreatic cancer cells, analyzed by spectral analysis and
fluorescent microscopy. (A) PANC-1 cells were cultured in medium supplemented with
50 µM curcumin for 24 hours, trypsinized, lysed in 100% methanol and subjected to
spectral analysis on a µQuant spectrophotometer at a 300-540 nm wavelength range. Red
= curcumin-treated cells; green = untreated cells; blue = methanol as a vehicle control.
(B) PANC-1 cells were cultured in medium supplemented with 50 µM curcumin (green)
for 24 hours and stained with the DNA dye DAPI to show nuclei (blue) followed by
imaging via fluorescence microscopy at 40X magnification. Results depicted in the figure
are representative of findings from 3 independent experiments.
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cytoplasmic, nuclear, and nucleolar pools visible by fluorescence microscopy. These
results indicate that curcumin is capable of entering PANC-1 cells in vitro and is nonspecific in its localization, suggesting multiple mechanisms of cytotoxicity.

Curcumin Decreases IAP protein and mRNA Expression
To determine the effects of curcumin on Survivin, cIAP1, cIAP2 and XIAP
expression, Western blot (Fig. 5A) and reverse-transcription PCR (Fig. 6A) were
performed following treatment with 10, 50 and 100 µM curcumin. Protein expression of
cIAP1, cIAP2 and XIAP were significantly decreased at 50 and 100 µM curcumin
treatment compared to untreated controls at 24 and 48 hours (Fig. 5B). In addition,
Survivin protein expression was significantly decreased after 50 µM curcumin treatment
for 24 hours and after 50 or 100 µM curcumin treatment for 48 hours. Moreover, 10 µM
curcumin was sufficient to significantly reduce cIAP2 expression after 48 hours of
treatment. Similarly, significant reduction in Survivin, cIAP1, cIAP2 and XIAP mRNA
expression was observed at 50 and 100 µM curcumin compared to untreated controls at
24 and 36 hours (Fig. 6B).

Discussion
Pancreatic cancer is a deadly disease that causes higher mortality rates annually
than other cancer types. Currently, surgical resection is one of the most effective
therapeutic approaches for pancreatic cancer. However, pancreatic cancer does not
exhibit notable signs or symptoms during early stages of development, making an early
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Figure 5. Expression of IAP proteins in PANC-1 cells following curcumin treatment. (A) Cells were cultured in medium
supplemented with 10-100 M curcumin for 24 and 48 hours. Whole-cell lysates were prepared and expression levels of Survivin,
cIAP1, cIAP2, XIAP and actin proteins were analyzed by Western blot as described in the Materials and Methods. Data are
representative of 3-4 independent experiments. (B) Protein levels of IAPs are presented as relative ratios to control cells without
curcumin treatment after normalization to -actin levels. Data are presented as mean (+ SEM). * p < 0.05, ** p < 0.01, *** p <
0.001, **** p < 0.0001, curcumin treatment versus untreated control.
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Figure 6. Expression of IAP mRNA following curcumin treatment in PANC-1 cells. (A) Cells were cultured in medium
supplemented with 10-100 M curcumin for 24 and 36 hours. RNA was extracted using the Trizol-chloroform extraction method
then converted to cDNA and probed using primers for Survivin, cIAP1, cIAP2, XIAP and GAPDH (Table 1). Data are
representative of 3 independent experiments. (B) mRNA levels of IAPs are presented as relative ratios to control cells without
curcumin treatment after normalization to GAPDH levels. Data are presented as mean (+ SEM). * p < 0.05, ** p < 0.01, *** p <
0.001, **** p < 0.0001, curcumin treatment versus untreated control.

diagnosis difficult. For this reason, most patients with advanced non-metastatic or
metastatic disease are ineligible for surgery and receive chemotherapy. Unfortunately, the
efficacy of chemotherapeutic agents is limited by emerging drug resistance [2, 3, 114,
115]. Therefore, the pancreatic cancer field is moving toward investigating therapeutic
approaches that target crucial mediators of chemoresistance. It has been well established
that evasion of cell death is a required event in the development of resistance to
chemotherapy [141, 142], with this resistance linked to the upregulation of anti-apoptotic
proteins such as the inhibitor of apoptosis (IAP) family members [143, 144].
Apoptosis is a type of cell death highly dependent on the activation of caspases
(cysteine-aspartic proteases) that cause endonuclease-mediated fragmentation of DNA
and cellular demise. This series of events is a prerequisite for progressive cellular
disassembly into apoptotic bodies that are subsequently consumed by phagocytic cells
[145]. The IAP family, particularly Survivin, cIAP1, cIAP2 and XIAP, are proteins that
have substantial roles in modulating the inactivation of apoptosis [120]. While the IAPs
have been shown to bind caspases, only XIAP directly inhibits caspases [146]. In
addition to its role in cell cycle regulation, Survivin is thought to bind active caspases
through cofactor proteins such as hepatitis B X-interacting protein (HBXIP) to prevent
amplification by cleavage of other pro-caspase isoforms [147, 148]. cIAP1 and cIAP2,
though capable of binding caspases, have been shown to inhibit apoptosis by interrupting
caspase activation through their E3 ubiquitin ligase function [149-151].
The nuclear factor-kappa B (NF-κB) transcription factor has been found to be
constitutively activated in pancreatic cancer [152, 153] and is known to regulate key
mediators of cancer cell survival, proliferation, angiogenesis, and metastasis [154-157].
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NF-κB has been shown to regulate the production of certain IAPs, including Survivin,
cIAP1, and XIAP [13, 154-157]. Furthermore, NF-κB activity and IAP expression have
been implicated in resistance to Gemcitabine [13, 158]. Gemcitabine induces an increase
in IAP expression in pancreatic cancer cells, particularly Survivin and XIAP, as well as
cIAP1 in lung cancer cells [159-162].
Indeed, studies targeting NF-κB [158, 160, 163, 164] or IAPs [161, 165, 166]
have demonstrated increased sensitivity to Gemcitabine. The increased sensitivity to
Gemcitabine following IAP reduction is the rationale for the use of second mitochondriaderived activator of caspases (Smac) mimetics. Smac is an endogenous pro-apoptotic
protein transcribed by the DIABLO gene. This protein promotes apoptosis by direct
interaction and inhibition of XIAP and Survivin proteins. Several Smac mimetics are
currently under investigation in clinical trials [37]. While these Smac mimetics have
shown promising results in preclinical trials in vitro and in vivo, both in the reduction of
IAP expression and in re-sensitization to Gemcitabine [167], they have no known effects
on NF-κB expression or activity. Recent studies have demonstrated that dual inhibition of
NF-κB activity and IAP expression may have superior benefits than reducing IAP
expression alone. Indeed, dual targeting of NF-κB and XIAP was more effective in resensitizing pancreatic adenocarcinoma cells to Gemcitabine therapy than XIAP
knockdown alone [161]. Thus, the optimal “next step” in the development of a
therapeutic strategy for pancreatic cancer involves compounds that target upstream
mediators of IAP expression, such as NF-κB, as well as multiple IAPs simultaneously.
Curcumin, a turmeric derivative, is a candidate for such a therapeutic agent. It has
been shown to inhibit pancreatic adenocarcinoma cell proliferation, survival, invasion
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and angiogenesis in vitro and in vivo [48, 168]. In addition, studies by Kunnumakkara et
al. have demonstrated that curcumin attenuates NF-κB activation, resulting in decreased
production of anti-apoptotic factors, including Survivin and cIAP1, as well as proangiogenic and metastatic factors, in MIA PaCa-2-derived xenograft tumors [13].
Multiple studies have demonstrated synergistic activity between curcumin and
Gemcitabine in pancreatic adenocarcinoma cells [48, 134, 135]. Interestingly, while
XIAP is considered to be the most potent regulator of apoptosis in humans, its levels
following curcumin treatment remain to be elucidated. Furthermore, the effect of
curcumin on mRNA expression of the IAPs remains to be investigated. This information
is essential to understanding whether curcumin’s effects on IAP expression are due to
transcriptional regulation or post-translational mechanisms. In this study, we explore
curcumin’s effects on protein and mRNA expression of a panel of key IAPs, including
Survivin, cIAP1, cIAP2 and XIAP in the pancreatic adenocarcinoma cell line PANC-1.
Phase I and II clinical trials have been conducted to evaluate the safety and efficacy of
curcumin alone and in combination with standard Gemcitabine-based chemotherapy [16,
109, 112, 113]. The major challenge to curcumin’s clinical use is poor bioavailability. A
recent Phase I clinical trial was conducted using a novel microparticle-based form of
curcumin called Theracurmin in combination with standard Gemcitabine-based
chemotherapy [109]. This study reported promising results, increasing plasma levels over
those reported in previous clinical trials, despite using approximately 5% of the dose of
curcumin used in earlier studies (400mg vs. 8g/day) while inducing minimal toxicity in
patients.
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While some controversy exists as to the Gemcitabine-sensitivity of the pancreatic
adenocarcinoma cell line MIA PaCa-2 [161, 163], PANC-1 cells are generally considered
to be resistant to Gemcitabine. Therefore, we investigated the sensitivity of these cells to
curcumin in vitro using AlamarBlue and Trypan blue exclusion viability assays. Our
results are consistent with those published using other viability assays in PANC-1 cells
[169-171], demonstrating dose- and time-dependent reduction in cell viability following
curcumin treatment (Fig. 2). In addition, Hoffmann modulation contrast microscopy
illustrates the morphology of PANC-1 cells following curcumin treatment (Fig. 3). Cells
treated with curcumin exhibit features characteristic of apoptotic cell death, including cell
shrinkage and membrane blebbing.
To further elucidate the possible mechanisms of action of curcumin in PANC-1
cells, the spectral properties of curcumin (Fig. 4A) were used to determine the
intracellular localization of the compound as analyzed by fluorescence microscopy (Fig.
4B). Consistent with the notion that curcumin exerts effects on multiple intracellular
signaling pathways [172-175], our results demonstrate that curcumin displays a pancellular localization.
To determine the effects of curcumin on IAP protein and mRNA expression, we
performed Western blot and RT-PCR analyses on curcumin-treated PANC-1 cells. Our
data demonstrate that curcumin reduces protein and mRNA levels of Survivin, cIAP1,
cIAP2 and XIAP (Fig. 5 and 6), with the most marked effects on IAP expression
demonstrated by cIAPS 1 and 2 and XIAP. Interestingly, while mRNA expression of
Survivin diminishes with increasing curcumin concentrations and incubation times,
Survivin’s protein level appears to be relatively stable at the highest dose (100 µM) and
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time (48 hours) evaluated, remaining at approximately 50% of the level in untreated
PANC-1 cells. These data suggest that mechanisms exist to stabilize Survivin protein
under conditions of curcumin treatment, despite a reduction in Survivin mRNA
production. This finding carries heavy implications for resistance to therapy, since
Survivin itself has been found to bind and stabilize XIAP, enhancing the latter’s caspase9 inhibiting activity [176]. Thus, while curcumin exerts potent effects on upstream (NFκB-mediated) signaling leading to reduced IAP expression, residual Survivin may
represent a key mechanisms for evasion of cell death in the context of this therapeutic
strategy.
In summary, our data demonstrate for the first time that curcumin is effective in
reducing expression of multiple IAPs critical to chemoresistance, both at the mRNA and
protein level, resulting in increased cell death in vitro. The ability to modulate multiple
members of the IAP family may prove to be a key factor in selecting compounds for
further study as selection of individual IAP-specific targeting has been less than effective.
Furthermore, we demonstrate that, of these IAPs, Survivin shows the least sensitivity to
curcumin-mediated downregulation, suggesting a possible role in resistance to curcumin
treatment, a phenomenon that we are currently investigating in our laboratory.
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Abstract
Pancreatic cancer has the highest mortality rates of all cancer types. One potential
explanation for the aggressiveness of this disease is that cancer cells have been found to
communicate with one another using membrane-bound vesicles known as exosomes.
These exosomes carry pro-survival molecules and increase the proliferation, survival, and
metastatic potential of recipient cells, suggesting that tumor-derived exosomes are
powerful drivers of tumor progression. Thus, to successfully address and eradicate
pancreatic cancer, it is imperative to develop therapeutic strategies that neutralize cancer
cells and exosomes simultaneously. Curcumin, a turmeric root derivative, has been
shown to have potent anti-cancer and anti-inflammatory effects in vitro and in vivo.
Recent studies have suggested that exosomal curcumin exerts anti-inflammatory
properties on recipient cells. However, curcumin’s effects on exosomal pro-tumor
function have yet to be determined. We hypothesized that curcumin alters the prosurvival role of exosomes from pancreatic cancer cells toward a pro-death role, resulting
in reduced cell viability of recipient pancreatic cancer cells. The main objective of this
study was to determine the functional alterations of exosomes released by pancreatic
cancer cells exposed to curcumin compared to exosomes from untreated pancreatic
cancer cells. We demonstrate, using an in vitro cell culture model, that curcumin is
incorporated into exosomes derived from curcumin-treated pancreatic cancer cells, and
that these exosomes reduce the viability of recipient pancreatic cancer cells. Collectively,
these data suggest that the efficacy of curcumin may be enhanced in pancreatic cancer
cells through exosomal facilitation.
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Introduction
Currently, pancreatic cancer is one of the most devastating diagnoses to receive. It
is responsible for one of the highest mortality rates among cancer types [2]. It is
anticipated that 48,960 people will be diagnosed with pancreatic cancer and 40,560
people will die from pancreatic cancer in the United States this year [1]. These
unacceptably high mortality rates are linked to inadequate screening tools and therapeutic
options, as well as the aggressive nature of the disease [4, 177]. This aggressiveness is
correlated with the influence of the tumor microenvironment, which is composed of
blood vessels, immune cells, fibroblasts, extracellular matrix and cancer cells [178]. The
signaling networks between the components of the tumor microenvironment are
important drivers of tumor growth. Investigations have shown that tumor-derived
extracellular vesicles such as exosomes are key modulators of this communication due to
their capacity to transport cancer-promoting material [103-106]. In order to successfully
treat pancreatic cancer, it is crucial to develop novel therapeutic strategies that
concomitantly target tumor cells and important mediators of the tumor microenvironment
such as exosomes.
Curcumin is a turmeric root constituent that has been considered as a potential
pancreatic cancer therapeutic agent. Studies have demonstrated lower cancer incidence in
countries with high curcumin consumption [10, 11] and preclinical studies have shown
that curcumin exhibits anti-cancer [12, 32, 47, 51, 133, 168, 179-186] and antiinflammatory [187-191] properties in different cancer types in vitro and in vivo.
Additionally, curcumin has synergistic effects with Gemcitabine, the gold standard
treatment for pancreatic cancer [48, 134, 135]. These encouraging results have prompted
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researchers to assess the efficacy of curcumin in the treatment of pancreatic cancer. Phase
I and II clinical trials have yielded promising results on the use of curcumin as part of
pancreatic cancer therapeutic strategies [16, 109, 112, 113, 136, 137]. However,
curcumin has low bioavailability and this is one of the major obstacles to its application
in the clinical setting. To overcome this, investigations have moved toward the
development of innovative delivery approaches for curcumin, such as liposomes and
nanoparticles, to enhance its bioavailability and efficacy [14, 91, 95, 97, 99, 100, 109,
192-208]. It has been demonstrated in various cancer types, including pancreatic cancer,
that curcumin’s solubility and efficacy is enhanced by liposomal delivery in vitro and in
vivo with minimal toxicity, providing promising evidence for clinical application [206209]. Studies performed with nanoparticle-based curcumin, Theracurmin, have indicated
that membrane encapsulation can improve the bioavailability of hydrophobic compounds
such as curcumin by increasing water solubility [14, 99]. Furthermore, phase I studies
with Theracurmin demonstrated that this treatment approach is non-toxic and results in
higher curcumin bio-distribution compared to non-encapsulated curcumin in patients with
pancreatic cancer [14, 100, 109]. In addition to being encapsulated in synthetic
nanoparticles, curcumin is able to be packaged in lymphoma-derived exosomes and retain
its anti-inflammatory function after delivery to recipient cells [210].
Collectively, these data suggest that curcumin is a suitable candidate for
pancreatic cancer therapy due to its anti-cancer and anti-inflammatory properties.
Moreover, curcumin has the potential to influence the role of exosomes in the tumor
microenvironment. Thus, the objective of this study was to evaluate the impact of
exosomal curcumin on recipient pancreatic cancer cells. The present study demonstrates,
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for the first time, that exosomes from curcumin-treated pancreatic cancer cells carry
curcumin and that these curcumin-containing exosomes reduce the viability of recipient
pancreatic cancer cells. These findings suggest that the effects of curcumin may extend to
other components of the tumor microenvironment through exosomes.

Materials and Methods
Cells and Culture Conditions
The pancreatic adenocarcinoma cell line PANC-1 was acquired from the
American Type Culture Collection (ATCC, catalog no. CRL-1469, Manassas, VA) and
maintained in Dulbecco’s modified Eagle medium (DMEM; ATCC, Manassas, VA)
supplemented with Normocin at a final concentration of 100 µg/mL (InvivoGen, San
Diego, CA), 100 units of penicillin, 100 µg/mL of streptomycin, 300 µg/mL of Lglutamine and 10% USDA-sourced heat-inactivated fetal bovine serum (Mediatech,
Manassas, VA). In all the experiments, cells were cultured at 37°C in a humidified
atmosphere containing 5% CO2 to 70-80% confluency prior to use.

Preparation of Solutions
Curcumin (Sigma Aldrich, St. Louis, MO) stock solutions (13.5 mM) were
prepared using DMSO and ethanol as solvents. Subsequent dilutions were made from this
stock solution in fully supplemented DMEM to a final concentration of 50 µM. Heparin
sodium salt (Sigma Aldrich, St. Louis, MO) was used to prepare a 50 mg/mL stock
solution in sterile water and used at a final concentration of 10 µg/mL. Recipient PANC1 cells were pre-treated with 10 µg/mL heparin in fully supplemented DMEM for 30
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minutes at 37°C, 5% CO2 prior to incubation with exosomes. Of note, 10 µg/mL heparin
was also added during the subsequent incubation with exosomes as well.

Exosome Isolation
Exosomes were isolated from conditioned media as previously described by
Savina et al. [211, 212] with minor modifications. Briefly, PANC-1 cells were cultured in
fifteen T75 flasks at 1.5 x 106 cells per flask and conditioned media (CM) was collected
following 24 hours of treatment with fully supplemented DMEM (for isolation of
curcumin-negative exosomes) or 50 µM of curcumin (for curcumin-positive exosome
isolation). The cellular debris and other impurities in the CM were eliminated by three
consecutive cycles of centrifugation. First, the CM was centrifuged in a Beckman Coulter
Allegra X-15R centrifuge (SX475OA rotor) at 400 x g for 10 minutes, then at 2000 x g
for 20 minutes, followed by centrifugation in a Thermo Scientific Sorvall Legend X1R
centrifuge (F15-8X50Y rotor) at 10,000 x g for 30 minutes. Subsequently exosomes were
isolated from the CM by ultracentrifugation in a Beckman XL-90 centrifuge equipped
with a SW-27 rotor at 24,000rpm for 16 hours at 4°C over a 30% sucrose cushion. The
exosomes within the sucrose cushion were washed with 1X PBS and centrifuged in a
Beckman XL-90 centrifuge equipped with a 70-Ti rotor at 31,000 rpm for 2 hours at 4°C.
The remaining pellet, the exosomal fraction, was resuspended in 500 µL of 1X PBS,
transferred to a microcentrifuge tube, and immediately used in subsequent assays.
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Exosome Detection and Validation
Acetylcholinesterase activity assays were performed to detect exosome presence
based on the protocols described by Savina et al. and Lancaster and Febbrario [211, 213]
with minor modifications. Briefly, 37.5 µL of the exosomal fraction were transferred into
each of three wells of a 96-well flat-bottom plate. 112.5 µL of 1.25 mM acetylthiocholine
(Sigma) and 150 µL of 0.1 mM 5,5’-dithio-bis(2-nitrobenzoic acid) (Sigma) were then
added to each well. The samples were immediately analyzed using a µQuant
spectrophotometer (Bio-Tek Inc., Winooski, VT) and changes in absorbance at 412 nm
were monitored every 5 minutes for 30 minutes. The exosome absorbance data were
analyzed using the KC Junior software (Bio-Tek Inc.). The results presented represent
acetylcholinesterase enzymatic activity after 30 minutes compared to control (reagents in
assay diluent, 1X PBS).
Nicomp 380 ZLS analysis (Particle Sizing Systems, Port Richey, FL) was used to
assess the size of the particles present in the exosome isolation fraction. Briefly, the
exosomal fraction was diluted 1:30 with 1X PBS in a 4 mL (1 cm x 1 cm) plastic cuvette
at 23°C and the size dispersion was measured using Nicomp 380 ZLS dynamic light
scattering (DLS) with a display range of 0.6 to 6000 nm. The sample was exposed to a
HeNe 5 mW laser using a wavelength of 639 nm. The data were analyzed using the
Nicomp Fit Model Type and PSS zpw 388 Nicomp software. Finally, real-time detection,
sizing, and quantification were performed using a NanoSight NS300 following the
manufacturer’s protocols (Malvern Instruments, Malvern, UK). Briefly, exosome isolates
were diluted 1:1000 in 1X PBS and sonicated in a water bath sonicator for 30 seconds to
prevent exosome aggregation. Samples were then loaded into the NS300 instrument and
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subjected to nanoparticle tracking analysis (NTA) yielding size distribution and
concentration (particles/mL). Acetylcholinesterase activity assays and NanoSight NTA
were performed in three independent experiments, while Nicomp DLS analysis was
performed in two independent experiments.

Spectral Studies
The spectral properties of curcumin, particularly a characteristic absorbance peak
at 420 nm, have been utilized in detecting the compound under experimental conditions.
These spectral analyses of exosomal curcumin were designed, with minor modifications,
based on studies detecting curcumin within cells [138-140]. Briefly, exosomes were
isolated as described above. To determine whether curcumin was coating the exterior
surface of exosomes, exosomal fractions were subjected to spectral analysis prior to
methanol-sonication disruption of exosomal membranes. To determine whether curcumin
was located in the interior of the exosomes, the exosomal fraction was resuspended in 1
mL of 100% methanol and sonicated to disrupt exosome membrane integrity. The
samples were then centrifuged at 10,000 rpm for 5 minutes at 4°C and the supernatant
was collected for absorbance analysis at 420 nm using a µQuant spectrophotometer
equipped with KC Junior software. Exosomes from untreated cells (curcumin-negative
exosomes) were also isolated and lysed in methanol and subjected to spectral analysis to
determine baseline auto-fluorescence of exosomes without curcumin. 1X PBS (for nonlysed exosome samples) or methanol (for lysed exosome samples) were used as negative
controls for this assay. Data are representative of three independent experiments.
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Fluorescence Imaging
Fluorescence microscopy was performed to detect the entry of exosomal
curcumin into recipient PANC-1 cells. Briefly, PANC-1 cells were cultured in 6-well
plates containing sterile cover slips at 3.0 x 105 cells per well and exposed for 24 hours to
curcumin-negative or curcumin-positive exosomes. Subsequently, cells were washed
three times with 1X PBS, followed by fixation with 4% paraformaldehyde overnight at 20°C and permeabilization using 0.1% Igepal in 1X PBS for 10 minutes at room
temperature. The cover slips were then washed three times with 1X PBS and placed onto
slides with the nuclear stain DAPI in mounting medium for 5 minutes. Stained slides
were imaged using a BZ-9000 BIOREVO fluorescence microscope (Keyence, Itasca, IL)
with a 40X magnification objective. In a separate experiment, PANC-1 cells were
incubated with 10 µg/mL of heparin for 30 minutes prior to exposure to curcuminpositive exosomes to determine exosomal curcumin delivery in the presence of heparin,
an inhibitor of exosomal uptake by recipient cells [214-216]. Results are representative of
three independent experiments; within each experiment, three images were acquired from
different portions of each slide to obtain a representative image. Quantification of
curcumin fluorescence per cell was performed using the BZ II analyzer software
(Keyence, Itasca, IL). For each image acquired (three per independent experiment, three
independent experiments), the hybrid cell count and adjust extension area software
features were used to calculate cell number based on DAPI staining, followed by
quantification of curcumin fluorescence. For each image acquired, curcumin fluorescence
was divided by cell number and multiplied by 100 and the averages of these values were
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obtained for three independent experiments. Graphs were generated using the Prism
(Graphpad, La Jolla, CA) software.

Cell Viability
Cell viability following exosomal curcumin entry was detected using the
AlamarBlue assay. Briefly, PANC-1 cells were cultured in 96-well flat-bottom plates at
1.0 x 104 cells per well in the presence of fully supplemented DMEM (untreated),
curcumin-negative exosomes, or curcumin-positive exosomes for 24, 48 and 72 hours.
Subsequently, the AlamarBlue reagent (Life Technologies, Grand Island, NY) was added
to each sample at a 10% final concentration and incubated at 37°C/5% CO2 for 2 hours.
Viability was analyzed by detection of absorbance at 570 nm using 600 nm as a reference
wavelength in a µQuant spectrophotometer. To determine whether any observed changes
in viability were due to exosome-mediated effects, a separate sample was pre-treated with
10 µg/mL heparin for 30 minutes prior to addition of curcumin-positive exosomes;
heparin was maintained during subsequent treatment with curcumin-positive exosomes.
Results presented are representative of three independent experiments and each treatment
(curcumin-negative exosomes, curcumin-positive exosomes, and heparin + curcuminpositive exosomes) is normalized to the untreated control.

Statistical Analysis
All statistical analyses in this study were performed using either one-way
ANOVA or Students’ t-test analyses using the Prism (Graphpad) software. Statistical
analysis of acetylcholinesterase activity assays was performed using Kruskal-Wallis one-
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way ANOVA with a post-hoc Dunn’s multiple comparison test. Analysis of curcumin
fluorescence was performed using an unpaired one-tailed Students’ t-test. Statistical
analysis of viability assays was performed using one-way ANOVA with a post-hoc
uncorrected Fisher’s LSD test. A probability of less than a 95% confidence limit (p <
0.05) was considered to be significant. Data are presented as mean + standard error of the
mean (SEM).

Results
Detection, Size Distribution and Quantification of Exosomal Particles
To confirm exosome isolation, known methods of exosome detection, sizing and
quantification were employed. Since it has previously been established that the
acetylcholinesterase enzyme is enriched in exosomes [217], an acetylcholinesterase
activity assay was used to detect the presence of exosomes in our isolates. Our data
demonstrate significantly increased acetylcholinesterase activity in exosome isolates
compared to control (assay reagents in 1X PBS) (Fig. 7A). No significant difference was
observed in acetylcholinesterase activity between exosomes derived from untreated
PANC-1 cells (curcumin-negative exosomes) and exosomes derived from PANC-1 cells
treated with 50 µM of curcumin (curcumin-positive exosomes). To further validate
exosome isolation, particle size was measured using two separate methods: Nicomp
dynamic light scattering (DLS) analysis and NanoSight nanoparticle tracking analysis
(NTA). Our data demonstrate that both exosome isolates (curcumin-negative exosomes
and curcumin-positive exosomes) contain particles within the established size range for
exosomes, 40-150 nm [218] (Fig. 7B-C). Finally, NanoSight NTA was utilized to
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Figure 7. Validation of exosome isolation. (A) Acetylcholinesterase activity assays were
used to detect exosomes in isolates from untreated PANC-1 cells (curcumin-negative
exosomes) or PANC-1 cells treated with 50 µM of curcumin for 24 hours (curcuminpositive exosomes) and compared to assay diluent, 1X PBS (control). (B) Nicomp
dynamic light scattering (DLS) analysis was used to measure size distribution of particles
in exosome isolates. (C) NanoSight nanoparticle tracking analysis (NTA) was used to
confirm size distribution of particles in exosome isolates. (D) Particle concentration
(particles/mL) was measured using NanoSight NTA. No significant differences were
observed in acetylcholinesterase activity, size distribution, or particle concentration
between curcumin-negative exosomes and curcumin-positive exosomes. Data are
represented as mean + SEM of three independent experiments, * p < 0.05, ** p < 0.01,
exosome fraction versus control.
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quantify exosome isolates (particles/mL). The amount of exosomes released from
curcumin-treated PANC-1 cells was not statistically different from the amount of
exosomes released from untreated PANC-1 cells (Fig. 7D).

Curcumin Detection within Exosomes
It has been previously reported that curcumin has an absorbance spectrum with a
peak at 420 nm [138-140]. This was used to detect its presence within exosomes using
spectrophotometric studies. To determine whether curcumin coats the exterior of
exosomes, whole exosomes isolated from curcumin-treated PANC-1 cells were subjected
to spectral analysis and compared to assay diluent (1X PBS) (Fig. 8A). These studies
demonstrate a lack of the characteristic absorbance peak corresponding to curcumin at
420 nm. To determine whether curcumin is incorporated into exosomes, exosomes
isolated from PANC-1 cells untreated or treated with 50 µM of curcumin for 24 hours
were isolated and lysed in 100% methanol. The absorbance peak of exosomes isolated
from curcumin-treated PANC-1 cells at 420 nm (lysed curcumin-positive exosomes;
green) was compared to exosomes isolated form PANC-1 cells not treated with curcumin
(lysed curcumin-negative exosomes; blue) or methanol-only blank samples (red) (Fig.
8B). Collectively, these data demonstrate that curcumin is not detectable in the exterior
surface of the exosomes but is rather located within the lumen of the exosomes.
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Figure 8. Spectrophotometric detection of curcumin within exosomes from PANC-1
cells. Exosomes were isolated from untreated PANC-1 cells (curcumin-negative
exosomes) or PANC-1 cells treated with 50 µM of curcumin for 24 hours (curcuminpositive exosomes). (A). Whole (non-lysed, blue) exosomes from curcumin-treated
PANC-1 cells were subjected to spectral analysis compared to vehicle (1X PBS blank,
red), in which optical density (OD) at 420 nm was measured. No peak in absorbance was
detected at 420 nm from whole (non-lysed) exosomes. (B) Methanol and sonication were
used to lyse exosomes from curcumin-treated PANC-1 cells (lysed curcumin-positive
exosomes, green) or exosomes from untreated PANC-1 cells (lysed curcumin-negative
exosomes, blue). A methanol-only blank (red) was used as a negative control for this
assay. A characteristic peak in OD at 420 nm was detected in lysed curcumin-positive
exosomes, but not in lysed curcumin-negative exosomes or the methanol-only blank.
Data are representative of three independent experiments.
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Entry of Exosomal Curcumin into Recipient PANC-1 Cells
To determine whether exosomal curcumin can be delivered into recipient PANC1 cells, the intrinsic fluorescence capacity of curcumin, with approximate excitation and
emission spectra of 420 and 520 nm, respectively [139, 140], was exploited using
fluorescence microscopy. Naïve PANC-1 cells were incubated with either curcuminnegative exosomes or curcumin-positive exosomes for 24 hours and subjected to
fluorescence microscopy. The DNA dye DAPI was used to visualize cell nuclei (blue).
Curcumin content (green) in recipient PANC-1 cells demonstrates a cytoplasmic pattern
excluding the nucleus (Fig. 9A). Interestingly, if recipient PANC-1 cells were pre-treated
with 10 µg/mL heparin, the cytoplasmic detection of curcumin is markedly reduced,
validating exosomal transfer of curcumin in these studies (Fig. 9A-B).

Exosomal Curcumin Reduces Recipient PANC-1 Cell Viability
The effects of exosomal curcumin on recipient PANC-1 cell viability were
assessed using AlamarBlue viability assays (Fig. 10). After exosome-mediated entry,
curcumin demonstrates inhibitory effects on recipient PANC-1 cell viability compared to
untreated controls. Furthermore, our data demonstrate that PANC-1 cell viability is
restored upon pre-treatment with 10 µg/mL heparin, an inhibitor of exosome binding
[214-216], implicating exosomal transfer of curcumin as a crucial mediator of reduced
cell viability in this system. Interestingly, an increase in PANC-1 cell viability after
exposure to curcumin-negative exosomes was noted. This is consistent with the notion
that tumor-derived exosomes have been shown to deliver cancer-driving factors to
recipient cells, promoting aggressive behavior [101, 102]. Our data indicate that
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Figure 9. Exosomal curcumin in recipient PANC-1 cells. Naïve PANC-1 cells were coincubated with exosomes from untreated PANC-1 cells (curcumin-negative exosomes) or
exosomes from PANC-1 cells treated with 50 µM of curcumin for 24 hours (curcuminpositive exosomes). In a separate culture, naïve recipient PANC-1 cells were treated with
10 µg/mL heparin to inhibit exosomal binding 30 minutes prior to and during coincubation with curcumin-positive exosomes (heparin + curcumin-positive exosomes).
After 24 hours, cells were washed and stained with DAPI for visualization of nuclei. (A)
Curcumin fluorescence (green) and DAPI (blue) were detected by fluorescence
microscopy at 40X magnification. (B) Quantification of curcumin fluorescence was
performed using the BZ II analyzer software. Data were collected in three separate
images per independent experiment, three independent experiments. ND = not detectable.
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Figure 10. Exosomal curcumin reduces recipient PANC-1 cell viability. Naïve recipient
PANC-1 cells were cultured for the indicated times with exosomes isolated from
untreated PANC-1 cells (curcumin-negative exosomes) or exosomes isolated from
PANC-1 cells treated with 50 µM of curcumin (curcumin-positive exosomes). In a
separate experiment, naïve recipient cells were treated with 10 µg/mL heparin prior to
and during incubation with curcumin-positive exosomes (heparin + curcumin-positive
exosomes). Viability was determined via AlamarBlue viability assays and exosome
treatments were compared to naïve PANC-1 cells not exposed to exosomes or heparin
(untreated). Data are represented as mean + SEM of three independent experiments, * p <
0.05, ** p < 0.01, *** p < 0.001 treatment versus untreated control.
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curcumin conserves its cytotoxic effects on recipient pancreatic cancer cells after
exosomal trafficking.

Discussion
Patients diagnosed with pancreatic cancer have abysmal survival rates because the
current treatment options are not sufficient to completely eradicate the disease. The most
effective available therapeutic approach is to resect the pancreas; however, only a
minimal percent of patients meet the criteria for surgery due to the lack of effective early
detection tools. Additionally, most patients relapse despite intensive post-surgery
treatment regimens [219]. The resistance to therapy and tumor aggressiveness observed
in pancreatic cancer are related to the effects of the components of the tumor
microenvironment [178]. Moreover, these effects are highly dependent on signaling
networks driven in part by tumor-derived extracellular vesicles such as exosomes [103106]. For instance, our group has previously shown that Survivin, a protein highly
expressed in cancers and essential for carcinogenesis, is localized in intra-cellular an
extracellular pools, and that extracellular Survivin enters cancer cells, increasing
proliferation, resistance, and invasive potential [101]. These results are consistent with
another study conducted by our laboratory that demonstrated that Survivin is transported
out of cancer cells via exosomes [102]. Exosomes have also been shown to transport
mutant KRAS proteins to colon cancer cells, increasing tumor growth [220, 221]. These
results suggest that exosomes have the ability to modulate the components of the tumor
microenvironment via the transfer of bioactive molecules that modulate cancer growth. In
addition to transporting cancer-promoting material within the tumor microenvironment,
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exosomes released from primary tumors have been demonstrated to aid in the formation
of a suitable metastatic environment that promotes the transition of non-cancerous cells
into pre-cancerous cells [222]. For instance, pancreatic cancer cell-derived exosomes
have been shown to prepare pre-metastatic organs for population with cancer cells in vivo
[223]. These results demonstrate the imperative role of exosomes in metastasis in various
cancer types including pancreatic cancer.
Curcumin has been considered a promising therapeutic agent for cancer treatment
due to its multi-dimensional anti-cancer properties. For instance, curcumin has been
shown to modulate signaling molecules essential for the progression of most cancer types
including pancreatic cancer [12, 48, 168]. Additionally, curcumin exhibits synergetic
effects with Gemcitabine in vitro and in vivo. In the context of the clinic, curcumin has a
tolerable consumption profile as demonstrated by phase I and II clinical trials [16, 109,
112]. One of the main obstacles to curcumin’s utility in the clinic is low biodistribution
[224]. In response to this, numerous investigations have developed alternative approaches
to enhance curcumin delivery [14, 91, 95, 97, 99, 100, 109, 192-208]. These studies
demonstrate the potential role of curcumin in pancreatic cancer therapy. However, it is
imperative to determine the role of curcumin in the pancreatic cancer microenvironment,
particularly in the context of exosomes.
Previous studies have shown that curcumin has a pan-cellular distribution in
breast cancer cells [139]. This finding may offer an explanation for curcumin’s multidimensional regulatory roles and its capacity to influence various cell signaling pathways.
Remarkably, our results indicate that curcumin is able to be packaged into exosomes
derived from pancreatic cancer cells treated with curcumin. Furthermore, our work shows
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exosomal curcumin enters recipient pancreatic cancer and is able to cause significant
cytotoxic effects on recipient pancreatic cancer cells. This is consistent with other studies
that demonstrated that curcumin’s cytotoxic effects on cancer cells are enhanced upon
encapsulation of curcumin in synthetic nanoparticles and micelles in vitro and in vivo [91,
95, 97, 99, 100, 192, 193, 195-208]. Our results demonstrate an approximate 50%
decrease in PANC-1 cell viability 72 hours after exosomal curcumin uptake. It is also
important to note that PANC-1 cell-derived exosomes devoid of curcumin increased
viability of recipient PANC-1 cells. This is consistent with the notion that tumor-derived
exosomes have a cancer-supportive role in the tumor microenvironment [101, 102]. It is
also noteworthy to mention that regardless of exosomal curcumin content, tumor-derived
exosomes carry pro-cancerous material [103-106]. However, our results demonstrate that
these exosomal components were not an impediment to curcumin’s cytotoxic function
after exosomal delivery into recipient pancreatic cancer cells.
In summary, our results provide new evidence of curcumin’s ability to expand its
anti-cancer functions from one pancreatic cancer cell to a recipient pancreatic cancer cell
with the aid of exosome transportation. These findings reveal that curcumin’s function
may not be restricted to individual tumor cells, but may also be extended to components
of the tumor microenvironment such as other tumor cells through exosomes. Exosomes
represent a crucial mechanism of communication between the components of the tumor
microenvironment and also for preparing future metastatic sites [222]. Thus, our results
contribute to a better understanding of the role of curcumin in intercellular
communication between pancreatic cancer cells and other components of the tumor
microenvironment (vascular smooth muscle, stromal cells or fibroblasts, and immune
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cells). Collectively, these discoveries highlight the promising role of curcumin as a
therapeutic agent for the treatment of pancreatic cancer due to its multi-dimensional anticancer properties.
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CHAPTER FOUR
DISCUSSION
Due to the minimal possibility of survival and devastating effects of treatment on
the quality of life of pancreatic cancer patients, it is essential to contribute scientific
efforts to the development of therapeutic strategies that circumvent barriers to the
eradication of this disease. This thesis is intended to provide insight into the mechanisms
of action underlying curcumin’s anti-cancer properties. It is our hope that, with the
contributions of others, this work will promote further progress in the future eradication
of pancreatic cancer.
This work began with the purpose of determining the mechanisms by which
natural agents such as curcumin can cause pancreatic cancer cell death and perhaps be
used to treat pancreatic cancer patients. Low incidence of cancer has been reported in
countries with high consumption of natural agents with anti-cancer properties, such as
curcumin, in contrast with those countries lacking such agents as part of the dietary
regimen [11]. These findings paved the way for our laboratory to consider curcumin as a
possible therapeutic agent for pancreatic cancer.
Thus, in conjunction with an established foundation of literature confirming
curcumin’s anti-cancer properties and its potential role in the modulation of the tumor
microenvironment, we developed aims to investigate the mechanisms by which curcumin
triggers cell death in pancreatic cancer. These studies were expanded to include
curcumin’s ability to be packaged in exosomes and carried to recipient pancreatic cancer
cells to induce further cell death.
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Our work began by demonstrating that curcumin is able to enter and cause
cytotoxic effects in pancreatic cancer cells. Indeed, our fluorescence microscopy and
spectral analyses demonstrated that curcumin enters PANC-1 cells and is distributed in a
ubiquitous pattern within these cells. Furthermore, curcumin significantly reduced
PANC-1 cell viability in a time- and dose-dependent manner. Interestingly, cellular
morphology following curcumin treatment, as observed by Hoffman modulation contrast
microscopy, demonstrated hallmarks of apoptosis including cell shrinkage and the
formation of blebs.
To effectively address chemotherapy resistance in pancreatic cancer, known
drivers of chemotherapy resistance were investigated in the context of curcumin
treatment. The inhibitor of apoptosis (IAP) proteins, which include Survivin, cIAP1,
cIAP2 and XIAP, are promising targets due to their key roles in cancer resistance [3744]. Thus, we investigated the effects of curcumin treatment on IAP protein and mRNA
expression in pancreatic cancer cells. Our data reveal that curcumin decreased both the
protein and mRNA expression of Survivin, cIAP1, cIAP2 and XIAP in PANC-1 cells in a
time- and dose-dependent manner. Therefore, together with our results from studies on
cell viability, we conclude that curcumin reduces pancreatic cancer cell viability in part
through reduction of pro-survival and chemo-resistance factors such as the IAP family.
Pancreatic cancer therapy resistance has also been strongly linked to the tumor
microenvironment, which is composed of blood vessels, stromal cells, immune cells, and
cancer cells [178]. For effective operation, these components require regulated
communication via biological signals including soluble factors and exosomes. Exosomes
are extracellular membrane-bound vesicles ranging from 40-150 nm that have been
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linked with cancer progression and metastasis due to their ability to transport important
oncoproteins that promote a suitable growth environment for cancer cells.
Due to the importance of exosomes in cancer [103-106], we chose to investigate
curcumin’s effects on this component of the tumor microenvironment. Exosomes were
isolated via the sucrose cushion-ultracentrifugation technique from PANC-1 cells treated
or untreated with curcumin. Exosome isolation was validated using acetylcholinesterase
activity assays and nanoparticle tracking analysis (NTA) and dynamic light scattering
(DLS) were used to determine particle size (NTA, DLS) and concentration (NTA).
Results from these studies demonstrated that there was no significant difference between
untreated and curcumin-treated conditions in terms of the size distribution or
concentration of particles released from these cells. Using spectral studies, curcumin’s
presence was detected within exosomes, but not on the surface of the exosomes,
providing valuable insight into the packaging of curcumin into exosomes from pancreatic
cancer cells treated with curcumin. Further investigation of the functional role of
curcumin within exosomes revealed that exosomal curcumin is delivered to recipient
pancreatic cancer cells and retains its cytotoxic effects upon delivery. Exosomal
curcumin delivery to recipient pancreatic cancer cells was demonstrated using
fluorescence microscopy, while cellular outcomes were assessed using the AlamarBlue
viability assay. Interestingly, a significant reduction in recipient PANC-1 cell viability
was observed following exposure to exosomal curcumin; this effect was reversed with a
blockade of exosomal binding to recipient cells using heparin.
The novelty and significance of these findings is highlighted by previous studies
by our lab and others that demonstrate that tumor-derived exosomes carry oncoproteins
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important for tumor progression, thus increasing viability and proliferation of recipient
pancreatic cancer cells [101, 102]. These findings are supported by our results, which
demonstrate that exosomes from untreated PANC-1 cells increase the viability of
recipient PANC-1 cells. In contrast, however, our findings demonstrate that the presence
of curcumin within tumor-derived exosomes is sufficient to reverse this pro-survival
signaling, leading to a reduction in recipient cell viability. Finally, the essential role of
exosomal delivery of curcumin in the reduction of recipient cell viability was
demonstrated using heparin, an inhibitor of exosome to recipient cell binding. In the
presence of heparin, the reduction of recipient cell viability was abolished, suggesting
that the previously observed cytotoxic effects were dependent upon exosome binding and
delivery into recipient cells.
In summary, the results presented in this thesis provide a significant contribution
to pancreatic cancer research by elucidating curcumin’s effects on IAP expression, thus
addressing key mediators of chemoresistance, as well as exosome composition and
function, expanding our knowledge of curcumin’s multi-dimensional nature (Fig. 11 and
Fig. 12). Collectively, these benefits pave the way for future research on multidimensional therapeutic approaches to pancreatic cancer including combinatorial
strategies incorporating standard chemotherapies as well as natural compounds such as
curcumin, offering the promise of overcoming resistance to chemotherapy and improving
chemoresistant patient outcomes. Finally, these findings on curcumin’s role in pancreatic
cancer have the potential to be extended to other types of cancer, ultimately contributing
to the eradication of cancer.
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Figure 11. Curcumin’s effects on IAP expression and exosomal function. (A) Curcumin
enters PANC-1 cells and decreases the protein and mRNA expression of IAPs,
culminating in apoptotic cell death. (B) Curcumin is packaged within exosomes and
released from PANC-1 cells. These curcumin-containing exosomes induce cytotoxic
effects in recipient PANC-1 cells. MVB = multi-vesicular bodies.
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Figure 12. Possible roles of curcumin in chemoresistance, the modulation of the tumor
microenvironment, and exosomal composition. (A) Curcumin has the potential to
overcome pancreatic cancer chemotherapy resistance due to its capacity to decrease
protein and mRNA expression of key mediators of resistance such as the IAPs. (B)
Curcumin may have the ability to modulate different components of the tumor
microenvironment via exosomal transport. (C) Curcumin’s presence within pancreatic
cancer cell-derived exosomes may interfere with the exosomal packaging of oncoproteins
essential for metastatic niche formation. C = curcumin, MVB = multi-vesicular bodies.
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APPENDIX A
FUTURE DIRECTIONS

Part 1: To determine the mechanism of action by which curcumin induces caspaseindependent apoptosis
Currently, therapy for pancreatic cancer consists of anti-metabolite drugs
(Gemcitabine), topoisomerase inhibitors (Irinotecan) and mitotic spindle stabilizers
(Paclitaxel). While these agents target different intracellular processes, all converge upon
induction of cell death by apoptosis, leading to the activation of caspases (cysteineasparic proteases) that cause endonuclease-mediated fragmentation of DNA and cellular
demise. Pre-clinical and clinical studies have extensively demonstrated that pancreatic
cancer cells acquire resistance to these therapies by up-regulating anti-apoptotic proteins,
such as the inhibitor of apoptosis (IAP) protein family, that prevent the activation of
caspases. Based on this thesis, curcumin effectively reduces the protein and mRNA
expression of the IAPs. However, IAP protein function is closely related to the inhibition
of caspase-dependent apoptosis; it is still unclear how curcumin may affect caspaseindependent apoptotic cell death to prevent cancer propagation. Hence, it is imperative to
conduct experiments to investigate curcumin’s capabilities to induce caspase-independent
cell death in the event that caspase-dependent cell death is circumvented by pancreatic
cancer cells. Since circumvention of caspase-dependent cell death is a common event in
the development of chemotherapy resistance, these studies will address one of the crucial
obstacles to the eradication of pancreatic cancer, which is the persistent resistance to
therapy. The objective of this study is to determine curcumin’s effects on intracellular
proteins crucial for activation of caspase-independent apoptosis in vitro and in vivo.
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Using an in vitro cell-based model, the expression levels of proteins essential for the
activation of caspase-independent apoposis, including apoptosis inducing factor (AIF),
endonuclease G (Endo G) and calpains, will be determined in the cytoplasm,
mitochondria, lysosomes and nucleus of pancreatic cancer cells (PANC-1, MIA PaCa-2,
Capan-1 and Capan-2) following curcumin treatment. Furthermore, studies using siRNAs
and Isothermal Titration Calorimetry (ITC) will be performed to confirm that the
modulation of these proteins is directly related to curcumin treatment. Using an in vivo
orthotopic PANC-1-derived xenograft model, tumor growth and expression of AIF, Endo
G and calpains will be determined following curcumin treatment.

Part 2: To investigate the effects of pancreatic adenocarcinoma cell-derived
exosomal curcumin on T regulatory cells (Tregs) in vitro
In the context of pancreatic cancer, components of the tumor microenvironment
including cancer cells, stromal cells and immune cells, have been linked to the aggressive
phenotype and chemoresistant nature of the disease. In particular, investigation of the
function of the immunosuppressive T regulatory cell, Treg, has gained increased attention
due to the ability of these cells to repress immune surveillance and immune targeting of
tumors. Associated with this, tumor-derived exosomes, which are present in the tumor
microenvironment, have been shown to have the ability to transport material between
components of the tumor microenvironment, including immune cells. Furthermore,
tumor-derived exosomes have been shown to suppress the anti-cancer functions of
recipient immune cells. For these reasons, exosomes have been considered significant
mediators of the tumor microenvironment. Interestingly, studies have shown that
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therapeutic compounds conserve their properties after being packaged into exosomes and
are capable of affecting recipient cells. Therefore, the release of exosomes can be used as
a therapeutic advantage, particularly in situations where low bioavailability of drugs
hinders their success. This thesis demonstrates that curcumin is able to be packaged
within exosomes and retain its anti-cancer function upon delivery to recipient pancreatic
cancer cells. Additionally, other studies have confirmed that curcumin retains its
immunomodulatory properties following exosomal trafficking, suggesting that exosomal
curcumin may aid in the reprogramming of immune system toward a cancer-targeting
profile. In this context, studies involving exosomal curcumin’s effects on Tregs may
provide significant insight into the role of curcumin on the immune component of the
tumor microenvironment. The objective of this study is to determine the effects of
exosomal curcumin on the immunosuppressive function of Tregs in vitro. To accomplish
this objective, exosomes isolated from PANC-1 cells cultured in the presence or absence
of curcumin will be used to treat Tregs from pancreatic cancer patients or healthy donors.
Subsequently, activation or suppression of Treg cells will be assayed using real-time PCR
(RT-PCR), enzyme-linked immunosorbent assays (ELISA) and flow cytometry profiling.
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